Sarep­ta's gene ther­a­py to be man­u­fac­tured at Catal­ent plant with 'op­er­a­tional chal­lenges' this spring

Catal­ent, the con­tract man­u­fac­tur­er in the process of over­haul­ing its op­er­a­tions, is man­u­fac­tur­ing Sarep­ta Ther­a­peu­tics’ new­ly ap­proved gene ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy at one …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER